Company Profile

**Industry Sector:** Pharmaceutical

**Company Overview:** Elysium is a Delaware corporation whose mission is to develop game-changing technologies that will (i) enhance the ability of pain patients and their physicians to employ effective opioid-based pain management, (ii) reduce the costly impact of prescription drug abuse on families and our economy; and (iii) save lives. Experts believe that Elysium's technologies are game-changing because they offer unprecedented protection against oral overdose, the primary route of abuse, and dramatically reduce the risk of diverting unused prescription opioids.

**Target Market(s):** Acute and chronic pain

Management

**Leadership:**
- Greg Sturmer, President and CEO
- Thomas Jenkins, PhD, EVP and CSO

**Scientific Advisors:**
- Bob Rappaport, MD, Former FDA Division of Anesthesia, Analgesia, and Addiction Products Director
- Lynn Webster, MD, Pain Specialist and VP Scientific Affairs at PRA Health Sciences
- Hilary Sheevers, PhD, President of Aclairo, former FDA Pharm / Tox reviewer

Key Value Drivers

**Technology*: Our XpiRx™ technology targets unprecedented diversion-resistance to drastically reduce the primary source of abused drugs. Our O2P™ technology targets protection against overdose from the co-ingestion of multiple pills, the primary route of abuse.

**Competitive Advantage:** Our technologies offer first- and best-in-class features that competitors' technologies are incapable of addressing. Our new therapeutic entity strategy has a highly attractive risk/return profile with a higher probability of success based on existing data demonstrating feasibility, and faster, lower cost 505(b)2 development path with multiple potential product launches within 3-5 years.

**Plan & Strategy:** Actively seeking strategic partners

* Technologies funded by the NIH – NIDA grants

Product Pipeline

1. **XpiRx:** We are initially applying our XpiRx technology to immediate release hydrocodone and oxycodone. Our lead XpiRx NME could be used with all oral opioids, and the 505(b)2 development path has been confirmed via FDA pre-IND interactions.

2. **O2P:** We are initially applying our O2P technology to immediate release hydrocodone and oxycodone. Our O2P technology is applicable to all oral opioids.

Published human data demonstrate the feasibility of both technologies.